ES 1

Drug Profile

ES 1

Alternative Names: ES1

Latest Information Update: 17 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Essentys AB
  • Class Osteoporosis therapies
  • Mechanism of Action Collagen stimulants; Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Osteoporosis

Highest Development Phases

  • No development reported Postmenopausal osteoporosis

Most Recent Events

  • 25 May 2006 This compound is still in active development
  • 25 May 2006 ES 1 is available for licensing (
  • 30 Sep 2003 Phase-II clinical trials in Postmenopausal osteoporosis in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top